Sequenex, MTI Pact Aims to Slash MedTech Development Hurdles

LOS ANGELES & ATLANTA – May 01, 2026 – In a move set to accelerate the development of next-generation medical devices, software firm Sequenex has announced a strategic partnership with MedTech Innovator (MTI), the world’s largest accelerator for medical technology startups. The collaboration will provide MTI’s highly-vetted portfolio companies with access to Sequenex’s regulatory-ready software platform, tackling one of the most significant barriers to market entry for emerging health-tech firms.

Sequenex will provide financial support to MTI and work directly with select startups, offering its pre-built, customizable NEX platform for connected medical devices such as continuous glucose monitors (CGMs), biosensors, and wearables. The partnership aims to drastically shorten development timelines and streamline the complex path to regulatory approval.

“Partnering with MedTech Innovator aligns perfectly with our mission to remove barriers to innovation in connected medical devices,” said John Krlin, CTO of Sequenex, in the announcement. “Many startups are building groundbreaking technologies but face significant challenges when it comes to software development, integration, and regulatory readiness. We’re excited to provide the tools and expertise needed to help these companies move faster and bring impactful solutions to patients.”

Paul Grand, Founder and CEO of MedTech Innovator, echoed the sentiment, highlighting the value of strategic partners. “Our carefully curated partners and sponsors serve a vital role in driving innovations to achieve their maximum potential, and we are thrilled to welcome Sequenex as our newest partner,” he stated. “Together, we look forward to improving patient outcomes and creating lasting value across the healthcare ecosystem.”

Tackling MedTech’s Twin Hurdles: Code and Compliance

For any technology startup, speed to market is critical. But in the medical device sector, this urgency is complicated by a second, non-negotiable imperative: patient safety, which is enforced through rigorous regulatory oversight. Innovators in the medtech space face a dual challenge: building sophisticated software and proving its safety and efficacy to bodies like the U.S. Food and Drug Administration (FDA) and European authorities under the Medical Device Regulation (MDR).

Unlike a bug in a consumer app, a software flaw in a medical device can have life-threatening consequences. This reality has led to a complex web of international standards, including ISO 13485 for quality management systems, IEC 62304 for the software development lifecycle, and ISO 14971 for risk management. Adherence is not optional; it is the price of entry. For startups, which often operate with limited resources and small teams, navigating this landscape is a monumental task.

Industry analyses show that many promising companies falter not because their core idea is flawed, but because they underestimate the time, cost, and expertise required for compliant software development. Treating regulatory documentation as an afterthought often leads to costly rework, significant delays in clinical trials, and even outright rejection by regulators, jeopardizing the entire venture.

A Platform for Acceleration

The Sequenex-MTI partnership directly targets this pain point. Instead of forcing each startup to build a compliant software stack from scratch, Sequenex provides its NEX platform as a powerful accelerator. Described as an “80% ready” software foundation, the platform offers a pre-built, yet customizable, framework that includes iOS and Android mobile applications, clinician and patient dashboards, and a secure, HIPAA-compliant cloud infrastructure.

The critical advantage lies in its design. The NEX platform is engineered from the ground up in an ISO 13485-certified environment, with development processes that adhere to IEC 62304 and integrate ISO 14971 risk management from day one. This means that startups using the platform inherit a foundation that is already aligned with global regulatory expectations.

By leveraging this platform, a startup developing a novel biosensor can focus its limited engineering resources on its unique hardware, proprietary algorithms, and clinical validation, rather than reinventing the wheel on secure data transmission, user authentication, or cloud storage. Furthermore, Sequenex’s approach generates Design History File (DHF)-ready documentation throughout the development process, dramatically streamlining the creation of a submission package for regulatory bodies and saving what could amount to months or years of work.

Plugging into a Proven Innovation Engine

By partnering with MedTech Innovator, Sequenex is integrating its solution into one of the most successful and respected innovation ecosystems in healthcare. MTI is not a typical accelerator; it is a powerhouse with a proven track record. Its 838 alumni companies have collectively raised an astounding $11 billion in follow-on funding and have successfully brought over 500 products to market, impacting millions of patients.

The process for entering this ecosystem is fiercely competitive. For its 2026 cohort, MTI received a record 1,800 applications, ultimately selecting just 65 startups—a top-tier group that has already demonstrated significant potential. These companies engage in a year-long program of mentorship and support, beginning with pitch opportunities at the Radar Forum in April and culminating with showcases at the Finals Competition in October.

Sequenex's role as a partner means its tools will be available to some of the world's most promising medtech innovators. This symbiotic relationship provides the startups with a critical technological advantage while giving Sequenex a front-row seat to cutting-edge medical advancements, creating a feedback loop that can further refine its platform for future innovations.

Powering the Future of Connected Health

This collaboration represents a strategic response to the evolving nature of healthcare, which is increasingly digital and connected. The rapid growth of wearables, remote patient monitoring, and data-driven diagnostics requires a new paradigm for innovation—one that is built on both agility and uncompromising quality.

By combining MTI’s world-class mentorship and industry network with Sequenex’s specialized software infrastructure, the partnership creates a more efficient pathway for bringing transformative technologies to market. This model of ecosystem collaboration, where specialized providers offer foundational support to a broad range of innovators, could become a blueprint for advancing the entire digital health sector.

Ultimately, the goal is to accelerate the transition of groundbreaking ideas from the lab to the clinic. For patients awaiting better diagnostic tools, more effective chronic disease management, and less invasive monitoring solutions, shortening that journey is not just a business objective; it is a critical step toward a healthier future.